|
||||||
|
 | |
| |
| Differntial gene expression between RNA A-to-I edited versus non-edited samples |
| |
| |
| The effects of the RNA editing to the stability of the RNA structures |
| |
| |
| |
|
Gene summary for HTR2C |
 Gene summary |
| Gene information | Gene symbol | HTR2C | Gene ID | 3358 |
| Gene name | 5-hydroxytryptamine receptor 2C | |
| Synonyms | 5-HT1C|5-HT2C|5-HTR2C|5HTR2C|HTR1C | |
| Cytomap | Xq23 | |
| Type of gene | protein-coding | |
| Description | 5-hydroxytryptamine receptor 2C5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled5-hydroxytryptamine receptor 1Cserotonin 5-HT-1C receptorserotonin 5-HT-2C receptor | |
| Modification date | 20200313 | |
| UniProtAcc | P28335, | |
| Context |
| Gene ontology of each this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Gene | GO ID | GO term | PubMed ID |
| HTR2C | GO:0006874 | cellular calcium ion homeostasis | 19057895 |
| HTR2C | GO:0007200 | phospholipase C-activating G protein-coupled receptor signaling pathway | 12970106 |
| HTR2C | GO:0010513 | positive regulation of phosphatidylinositol biosynthetic process | 19057895 |
| HTR2C | GO:0019934 | cGMP-mediated signaling | 12970106 |
| HTR2C | GO:0042493 | response to drug | 18703043 |
| HTR2C | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 19057895 |
Top |
RNA A-to-I events for HTR2C |
| RNA A-to-I editing events in the ROSMAP, MSBB, and Mayo data sets based on Ensembl gene isoform structure. * This pie chart shows the number of RNA A-to-I editing events in different types of transcripts (# event, percentage). |
 |
| RNA editing frequencies across three data sets. |
 |
| The number of RNA A-to-I editing events in different types of transcripts (# event, percentage). |
 |
| RNA A-to-I editing events in AD. |
| ADediting_1486306(114584359, +), ADediting_1486307(114616569, +), ADediting_1486308(114617397, +), ADediting_1486309(114617403, +), ADediting_1486310(114621020, +), ADediting_1486311(114661199, +), ADediting_1486312(114683609, +), ADediting_1486313(114848119, +), ADediting_1486314(114848121, +), ADediting_1486315(114848125, +), ADediting_1486316(114848126, +), ADediting_1486317(114848131, +), ADediting_1486318(114865909, +), ADediting_1486319(114902794, +), ADediting_1486320(114908474, +), |
Top |
RNA editing positional annotations for HTR2C using Annovar |
| Protein coding RNA editing(s). |
| ADeditome ID | Position | Variant type | ENST | NTchange | AAchange | SIFT_score | Polyphen2_HVAR_score | PROVEAN_pred |
| ADediting_1486313 | chrX_114848119_+ | nonsynonymous SNV | ENST00000276198.6 | c.A466G | p.I156V | 0.053 | 0.155 | -0.79 |
| ADediting_1486313 | chrX_114848119_+ | nonsynonymous SNV | ENST00000371951.5 | c.A466G | p.I156V | 0.053 | 0.155 | -0.79 |
| ADediting_1486314 | chrX_114848121_+ | nonsynonymous SNV | ENST00000276198.6 | c.A468G | p.I156M | 0.001 | 0.971 | -2.29 |
| ADediting_1486314 | chrX_114848121_+ | nonsynonymous SNV | ENST00000371951.5 | c.A468G | p.I156M | 0.001 | 0.971 | -2.29 |
| ADediting_1486315 | chrX_114848125_+ | nonsynonymous SNV | ENST00000276198.6 | c.A472G | p.N158D | 0.029 | 0.98 | -3.39 |
| ADediting_1486315 | chrX_114848125_+ | nonsynonymous SNV | ENST00000371951.5 | c.A472G | p.N158D | 0.029 | 0.98 | -3.39 |
| ADediting_1486316 | chrX_114848126_+ | nonsynonymous SNV | ENST00000276198.6 | c.A473G | p.N158S | 0.052 | 0.973 | -3.2 |
| ADediting_1486316 | chrX_114848126_+ | nonsynonymous SNV | ENST00000371951.5 | c.A473G | p.N158S | 0.052 | 0.973 | -3.2 |
| ADediting_1486317 | chrX_114848131_+ | nonsynonymous SNV | ENST00000276198.6 | c.A478G | p.I160V | 0.063 | 0.167 | -0.82 |
| ADediting_1486317 | chrX_114848131_+ | nonsynonymous SNV | ENST00000371951.5 | c.A478G | p.I160V | 0.063 | 0.167 | -0.82 |
| Gene structure information of RNA editing(s). |
| ADeditome ID | Position | Variant type |
| ADediting_1486306 | chrX_114584359_+ | UTR5 |
| ADediting_1486307 | chrX_114616569_+ | intronic |
| ADediting_1486308 | chrX_114617397_+ | intronic |
| ADediting_1486309 | chrX_114617403_+ | intronic |
| ADediting_1486310 | chrX_114621020_+ | intronic |
| ADediting_1486311 | chrX_114661199_+ | intronic |
| ADediting_1486312 | chrX_114683609_+ | intronic |
| ADediting_1486313 | chrX_114848119_+ | exonic |
| ADediting_1486314 | chrX_114848121_+ | exonic |
| ADediting_1486315 | chrX_114848125_+ | exonic |
| ADediting_1486316 | chrX_114848126_+ | exonic |
| ADediting_1486317 | chrX_114848131_+ | exonic |
| ADediting_1486318 | chrX_114865909_+ | intronic |
| ADediting_1486319 | chrX_114902794_+ | intronic |
| ADediting_1486320 | chrX_114908474_+ | UTR3 |
| Repat-regional RNA editing(s). |
| ADeditome ID | Position | Repeat family | Repeat sub family | Repeat name |
| ADediting_1486307 | chrX_114616569_+ | SINE | Alu | Name=AluSx1 |
| ADediting_1486308 | chrX_114617397_+ | SINE | Alu | Name=AluJb |
| ADediting_1486309 | chrX_114617403_+ | SINE | Alu | Name=AluJb |
| ADediting_1486310 | chrX_114621020_+ | SINE | Alu | Name=AluSz |
| ADediting_1486311 | chrX_114661199_+ | SINE | Alu | Name=AluY |
| ADediting_1486312 | chrX_114683609_+ | SINE | Alu | Name=AluSx1 |
| ADediting_1486318 | chrX_114865909_+ | SINE | Alu | Name=AluSx |
| ADediting_1486319 | chrX_114902794_+ | SINE | Alu | Name=AluSx |
Top |
RNA A-to-I editing events in the alternative splicing sites for HTR2C |
| RNA A-to-I editing(s) in the alternative splicing sites. |
| AStype | ADeditomID | Editing position | AS position | AS direction | Exonic location | Wildtype sequence | Wildtype splicing strength | RNA edited sequence | RNA edited splicing strength |
| Differential pencent of spliced in (PSI) between RNA A-to-I edited and non-edited samples |
Top |
Differntial gene expression between RNA A-to-I edited versus non-edited samples for HTR2C |
| Distribution of the averaged gene expression in AD and control with or without RNA A-to-I editing event. * The grey color means N/A. |
| Distribution of the averaged gene isoform expression in AD and control with or without RNA A-to-I editing event. |
 | |
 | |
 | |
| - Differentially expressed gene between RNA A-to-I edited samples versus non-edited samples. * Click on the image to enlarge it in a new window. |
 |
 |
 |
 |
 |
 |
| - Differentially expressed transcript between RNA A-to-I edited samples versus non-edited samples. * Click on the image to enlarge it in a new window. |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
| ADeditome ID | Chr | Positoing | Skipped exon | ENSG | ENSTs |
Top |
Protein coding region RNA A-to-I editings for HTR2C |
| - Lollipop plot for RNA A-to-I editings across protein structure. * Click on the image to enlarge it in a new window. |
 |
Top |
The effects of the RNA editing to the miRNA binding sites for HTR2C |
| RNA A-to-I editings in the ROSMAP, MSBB, and Mayo data sets based on Ensembl gene isoform structure. |
 |
| RNA A-to-I editing in the 3'-UTR regions of mRNA gained miRNA binding sites. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-17-3p | chrX | 114908470 | 114908477 | 8mer-1a | 114908456 | 114908477 | 140 | -12.65 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-1910-5p | chrX | 114908467 | 114908473 | 7mer-m8 | 114908454 | 114908474 | 140 | -12.67 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-544a | chrX | 114908472 | 114908478 | 7mer-m8 | 114908456 | 114908479 | 170 | -20.36 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-17-3p | chrX | 114908470 | 114908477 | 8mer-1a | 114908456 | 114908477 | 140 | -12.65 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-1910-5p | chrX | 114908467 | 114908473 | 7mer-m8 | 114908454 | 114908474 | 140 | -12.67 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-544a | chrX | 114908472 | 114908478 | 7mer-m8 | 114908456 | 114908479 | 170 | -20.36 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-17-3p | chrX | 114908470 | 114908477 | 8mer-1a | 114908456 | 114908477 | 140 | -12.65 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-1910-5p | chrX | 114908467 | 114908473 | 7mer-m8 | 114908454 | 114908474 | 140 | -12.67 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-544a | chrX | 114908472 | 114908478 | 7mer-m8 | 114908456 | 114908479 | 170 | -20.36 |
| RNA A-to-I editing in the 3'-UTR regions of mRNA lost miRNA binding sites. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-20b-3p | chrX | 114908470 | 114908477 | 8mer-1a | 114908456 | 114908477 | 140 | -13.66 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-4540 | chrX | 114908467 | 114908473 | 7mer-m8 | 114908455 | 114908474 | 144 | -14.07 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-20b-3p | chrX | 114908470 | 114908477 | 8mer-1a | 114908456 | 114908477 | 140 | -13.66 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-4540 | chrX | 114908467 | 114908473 | 7mer-m8 | 114908455 | 114908474 | 144 | -14.07 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-20b-3p | chrX | 114908470 | 114908477 | 8mer-1a | 114908456 | 114908477 | 140 | -13.66 |
| ADediting_1486320 | chrX_114908474_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-4540 | chrX | 114908467 | 114908473 | 7mer-m8 | 114908455 | 114908474 | 144 | -14.07 |
| RNA A-to-I editing in lncRNA gained miRNA binding sites. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in lncRNA lost miRNA binding sites. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to lncRNA. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs lost binding to lncRNA. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| RNA A-to-I editing in miRNAs gained binding to the 3'-UTR region of mRNA. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| ADediting_1337757 | chr7_5495852_- | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-589-3p | chrX | 114907875 | 114907881 | 7mer-m8 | 114907857 | 114907882 | 147 | -13.45 |
| ADediting_1337757 | chr7_5495852_- | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-589-3p | chrX | 114907875 | 114907881 | 7mer-m8 | 114907857 | 114907882 | 147 | -13.45 |
| ADediting_1337757 | chr7_5495852_- | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-589-3p | chrX | 114907875 | 114907881 | 7mer-m8 | 114907857 | 114907882 | 147 | -13.45 |
| ADediting_1391023 | chr8_140732605_- | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-151a-3p | chrX | 114908397 | 114908403 | 7mer-m8 | 114908384 | 114908404 | 140 | -14.16 |
| ADediting_1391023 | chr8_140732605_- | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-151a-3p | chrX | 114908397 | 114908403 | 7mer-m8 | 114908384 | 114908404 | 140 | -14.16 |
| ADediting_1391023 | chr8_140732605_- | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-151a-3p | chrX | 114908397 | 114908403 | 7mer-m8 | 114908384 | 114908404 | 140 | -14.16 |
| ADediting_1471003 | chr9_63819626_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-4477b | chrX | 114909688 | 114909694 | 7mer-m8 | 114909672 | 114909695 | 155 | -10.23 |
| ADediting_1471003 | chr9_63819626_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-4477b | chrX | 114909688 | 114909694 | 7mer-m8 | 114909672 | 114909695 | 155 | -10.23 |
| ADediting_1471004 | chr9_63819627_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-4477b | chrX | 114908031 | 114908038 | 8mer-1a | 114908020 | 114908038 | 152 | -15.47 |
| ADediting_1471004 | chr9_63819627_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-4477b | chrX | 114908031 | 114908038 | 8mer-1a | 114908020 | 114908038 | 152 | -15.47 |
| ADediting_1471004 | chr9_63819627_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-4477b | chrX | 114908031 | 114908038 | 8mer-1a | 114908020 | 114908038 | 152 | -15.47 |
| ADediting_1535954 | chr14_101045974_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-381-3p | chrX | 114909995 | 114910001 | 7mer-m8 | 114909981 | 114910002 | 146 | -14.25 |
| ADediting_1535954 | chr14_101045974_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-381-3p | chrX | 114909995 | 114910001 | 7mer-m8 | 114909981 | 114910002 | 146 | -14.25 |
| ADediting_98289 | chr1_32086992_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-5585-3p | chrX | 114908830 | 114908836 | 7mer-m8 | 114908817 | 114908837 | 158 | -24.53 |
| ADediting_98289 | chr1_32086992_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-5585-3p | chrX | 114908830 | 114908836 | 7mer-m8 | 114908817 | 114908837 | 158 | -24.53 |
| RNA A-to-I editing in miRNAs lost binding to the 3'-UTR mRNA. |
| ADeditom_ID | Position | ENSG | ENST | Transcript name | miRNA ID | Chromosome | Targt | Targetscan end | Targetscan score | Miranda start | Miranda end | Miranda score | Miranda energy |
| ADediting_1097295 | chr3_85385762_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-5688 | chrX | 114907112 | 114907118 | 7mer-m8 | 114907094 | 114907119 | 154 | -13.2 |
| ADediting_1471003 | chr9_63819626_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-4477b | chrX | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| ADediting_1471003 | chr9_63819626_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-4477b | chrX | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| ADediting_1471004 | chr9_63819627_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-4477b | chrX | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| ADediting_1471004 | chr9_63819627_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-4477b | chrX | 114909447 | 114909454 | 8mer-1a | 114909431 | 114909454 | 146 | -12.89 |
| ADediting_1535951 | chr14_100874558_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-337-3p | chrX | 114908380 | 114908386 | 7mer-m8 | 114908367 | 114908387 | 143 | -9.62 |
| ADediting_1535951 | chr14_100874558_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-337-3p | chrX | 114908380 | 114908386 | 7mer-m8 | 114908367 | 114908387 | 143 | -9.62 |
| ADediting_1535951 | chr14_100874558_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-337-3p | chrX | 114908380 | 114908386 | 7mer-m8 | 114908367 | 114908387 | 143 | -9.62 |
| ADediting_1535953 | chr14_101045971_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-381-3p | chrX | 114908417 | 114908423 | 7mer-m8 | 114908403 | 114908424 | 140 | -11.01 |
| ADediting_1535953 | chr14_101045971_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-381-3p | chrX | 114908417 | 114908423 | 7mer-m8 | 114908403 | 114908424 | 140 | -11.01 |
| ADediting_1535953 | chr14_101045971_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-381-3p | chrX | 114908417 | 114908423 | 7mer-m8 | 114908403 | 114908424 | 140 | -11.01 |
| ADediting_1535954 | chr14_101045974_+ | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-381-3p | chrX | 114908417 | 114908423 | 7mer-m8 | 114908403 | 114908424 | 140 | -11.01 |
| ADediting_1535954 | chr14_101045974_+ | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-381-3p | chrX | 114908417 | 114908423 | 7mer-m8 | 114908403 | 114908424 | 140 | -11.01 |
| ADediting_1535954 | chr14_101045974_+ | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-381-3p | chrX | 114908417 | 114908423 | 7mer-m8 | 114908403 | 114908424 | 140 | -11.01 |
| ADediting_291761 | chr11_93733708_- | ENSG00000147246.10 | ENST00000276198.6 | HTR2C-201 | hsa-miR-1304-3p | chrX | 114907936 | 114907942 | 7mer-m8 | 114907921 | 114907943 | 142 | -14.06 |
| ADediting_291761 | chr11_93733708_- | ENSG00000147246.10 | ENST00000371950.3 | HTR2C-202 | hsa-miR-1304-3p | chrX | 114907936 | 114907942 | 7mer-m8 | 114907921 | 114907943 | 142 | -14.06 |
| ADediting_291761 | chr11_93733708_- | ENSG00000147246.10 | ENST00000371951.5 | HTR2C-203 | hsa-miR-1304-3p | chrX | 114907936 | 114907942 | 7mer-m8 | 114907921 | 114907943 | 142 | -14.06 |
| Differentially expressed gene-miRNA network |
Top |
The effects of the RNA editing to the stability of the RNA structures for HTR2C |
| - RNA A-to-I editing in mRNA. * Click on the image to enlarge it in a new window. |
| ENST | ENST type | RNA structure without RNA A-to-I editing. | RNA structure with RNA A-to-I editing. |
| ENST00000371951.5 | protein_coding |  |  |
| ENST00000371950.3 | protein_coding |  |  |
| ENST00000276198.6 | protein_coding |  |  |
| RNA A-to-I editing in miRNA. |
| ADeditom_ID | ENST | mir_ID | Editing_Information | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
| RNA A-to-I editing in mRNA. |
| ADeditom_ID | ENST | Editing_Information | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
| ADediting_1486306 | ENST00000371951.5 | chrX_114584359_+ | 282 | -1019.90 | -1020.20 | -1028.50 |
| ADediting_1486313 | ENST00000371951.5 | chrX_114848119_+ | 1285 | -1020.20 | -1020.20 | -1028.50 |
| ADediting_1486314 | ENST00000371951.5 | chrX_114848121_+ | 1287 | -1020.20 | -1020.20 | -1028.50 |
| ADediting_1486315 | ENST00000371951.5 | chrX_114848125_+ | 1291 | -1020.30 | -1020.20 | -1028.50 |
| ADediting_1486316 | ENST00000371951.5 | chrX_114848126_+ | 1292 | -1020.20 | -1020.20 | -1028.50 |
| ADediting_1486317 | ENST00000371951.5 | chrX_114848131_+ | 1297 | -1022.50 | -1020.20 | -1028.50 |
| ADediting_1486320 | ENST00000371951.5 | chrX_114908474_+ | 3255 | -1026.90 | -1020.20 | -1028.50 |
| ADediting_1486306 | ENST00000371950.3 | chrX_114584359_+ | 278 | -1343.00 | -1343.30 | -1349.70 |
| ADediting_1486320 | ENST00000371950.3 | chrX_114908474_+ | 3065 | -1350.00 | -1343.30 | -1349.70 |
| ADediting_1486306 | ENST00000276198.6 | chrX_114584359_+ | 274 | -1372.60 | -1372.90 | -1381.20 |
| ADediting_1486313 | ENST00000276198.6 | chrX_114848119_+ | 1186 | -1372.90 | -1372.90 | -1381.20 |
| ADediting_1486314 | ENST00000276198.6 | chrX_114848121_+ | 1188 | -1372.90 | -1372.90 | -1381.20 |
| ADediting_1486315 | ENST00000276198.6 | chrX_114848125_+ | 1192 | -1373.00 | -1372.90 | -1381.20 |
| ADediting_1486316 | ENST00000276198.6 | chrX_114848126_+ | 1193 | -1372.90 | -1372.90 | -1381.20 |
| ADediting_1486317 | ENST00000276198.6 | chrX_114848131_+ | 1198 | -1375.20 | -1372.90 | -1381.20 |
| ADediting_1486320 | ENST00000276198.6 | chrX_114908474_+ | 3156 | -1379.60 | -1372.90 | -1381.20 |
| RNA A-to-I editing in lncRNA. |
| ADeditom_ID | ENST | Editing_Information | Editing_Position | MFE_withoneAI | MFE_withoutAI | MFE_withmultipleAI |
Top |
Relation with ADAR for HTR2C |
| Correlation between ADAR gene expression and RNA editing frequency |
| Tissue | ADeditomID | position | ADAR1 (p-val) | ADAR1 (coeff.) | ADAR2 (p-val) | ADAR2 (coeff.) | ADAR3 (p-val) | ADAR3 (coeff.) |
| Correlation between ADAR gene expression and this gene's expression |
| Tissue | ADAR1 (p-val) | ADAR1 (coeff.) | ADAR2 (p-val) | ADAR2 (coeff.) | ADAR3 (p-val) | ADAR3 (coeff.) |
| DLPFC | 7.35403049813063e-43 | 0.676724771169145 | 1.99829952313992e-36 | 0.635186393926751 | 0.20524582403646 | -0.0721440470541984 |
| AC | 6.71915662568212e-56 | 0.795586692072815 | 7.98274306553362e-63 | 0.822898717556029 | 0.743373186512103 | -0.0208079779868235 |
| PCC | 1.23765743596229e-07 | 0.371286723701664 | 4.91546522880669e-06 | 0.323734750190982 | 0.751681319585029 | 0.0230438036894937 |
| TCX | 3.32483302310043e-19 | 0.647693517318668 | 4.48015518048847e-16 | 0.600638174762338 | 0.00448531751406268 | -0.230824764374035 |
| FP | 0.0019347897496157 | 0.230839483902303 | 1.13818809493324e-08 | 0.411663195773762 | 0.0685642019323021 | -0.136831977181132 |
| PG | 3.94627941131871e-09 | 0.414806385749143 | 4.16142321430817e-09 | 0.414243911480397 | 0.0686951914500237 | -0.133780819408222 |
Top |
Relation with AD stages for HTR2C |
| Correlation between AD stages and RNA editing frequency |
| Tissue | ADeditomID | position | P-val | Coeff. |
| IFG | ADediting_1486313 | chrX_114848119_+ | 0.0354713369979928 | 0.422303326441651 |
| IFG | ADediting_1486314 | chrX_114848121_+ | 0.0354713369979928 | 0.422303326441651 |
| IFG | ADediting_1486316 | chrX_114848126_+ | 0.0354713369979928 | 0.422303326441651 |
| IFG | ADediting_1486317 | chrX_114848131_+ | 0.0354713369979928 | 0.422303326441651 |
| Correlation between AD stages and this gene's expression |
| Tissue | P-val | Coeff. |
Top |
RelatedDrugs for HTR2C |
| Approved drugs targeting this gene. (DrugBank Version 5.1.0 2018-04-02) |
| Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| HTR2C | P28335 | DB00246 | Ziprasidone | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00247 | Methysergide | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00248 | Cabergoline | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00321 | Amitriptyline | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00363 | Clozapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00370 | Mirtazapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00408 | Loxapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00434 | Cyproheptadine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00458 | Imipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00540 | Nortriptyline | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00543 | Amoxapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00623 | Fluphenazine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00696 | Ergotamine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00726 | Trimipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00777 | Propiomazine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00805 | Minaprine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB01224 | Quetiapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB01267 | Paliperidone | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB04871 | Lorcaserin | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB06153 | Pizotifen | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB06216 | Asenapine | 5-hydroxytryptamine receptor 2C | small molecule | approved |
| HTR2C | P28335 | DB00574 | Fenfluramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|illicit|investigational|withdrawn |
| HTR2C | P28335 | DB01191 | Dexfenfluramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|illicit|investigational|withdrawn |
| HTR2C | P28335 | DB00193 | Tramadol | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00334 | Olanzapine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00413 | Pramipexole | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00589 | Lisuride | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00656 | Trazodone | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00714 | Apomorphine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00734 | Risperidone | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00934 | Maprotiline | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB01142 | Doxepin | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB01151 | Desipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB01200 | Bromocriptine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB01238 | Aripiprazole | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB01403 | Methotrimeprazine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB04948 | Lofexidine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB06148 | Mianserin | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB06594 | Agomelatine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational |
| HTR2C | P28335 | DB00477 | Chlorpromazine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved |
| HTR2C | P28335 | DB01242 | Clomipramine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved |
| HTR2C | P28335 | DB01392 | Yohimbine | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved |
| HTR2C | P28335 | DB01186 | Pergolide | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|vet_approved|withdrawn |
| HTR2C | P28335 | DB01079 | Tegaserod | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|withdrawn |
| HTR2C | P28335 | DB06144 | Sertindole | 5-hydroxytryptamine receptor 2C | small molecule | approved|investigational|withdrawn |
| HTR2C | P28335 | DB00420 | Promazine | 5-hydroxytryptamine receptor 2C | small molecule | approved|vet_approved |
| HTR2C | P28335 | DB00472 | Fluoxetine | 5-hydroxytryptamine receptor 2C | small molecule | approved|vet_approved |
| HTR2C | P28335 | DB01149 | Nefazodone | 5-hydroxytryptamine receptor 2C | small molecule | approved|withdrawn |
Top |
RelatedDiseases for HTR2C |
| Diseases associated with this gene. (DisGeNet 4.0) |
| Gene | Disease ID | Disease name | # pubmeds | Source |
| HTR2C | C0001973 | Alcoholic Intoxication, Chronic | 5 | PSYGENET |
| HTR2C | C0005586 | Bipolar Disorder | 5 | PSYGENET |
| HTR2C | C0011570 | Mental Depression | 5 | PSYGENET |
| HTR2C | C0011581 | Depressive disorder | 5 | PSYGENET |
| HTR2C | C0041696 | Unipolar Depression | 5 | PSYGENET |
| HTR2C | C0525045 | Mood Disorders | 5 | PSYGENET |
| HTR2C | C1269683 | Major Depressive Disorder | 5 | PSYGENET |
| HTR2C | C0036341 | Schizophrenia | 4 | PSYGENET |
| HTR2C | C0524620 | Metabolic Syndrome X | 3 | CTD_human |
| HTR2C | C0028754 | Obesity | 2 | CTD_human |
| HTR2C | C0043094 | Weight Gain | 2 | CTD_human |
| HTR2C | C0085159 | Seasonal Affective Disorder | 2 | PSYGENET |
| HTR2C | C0009171 | Cocaine Abuse | 1 | PSYGENET |
| HTR2C | C0027796 | Neuralgia | 1 | CTD_human |
| HTR2C | C0038587 | Substance Withdrawal Syndrome | 1 | CTD_human |
| HTR2C | C0038870 | Neuralgia, Supraorbital | 1 | CTD_human |
| HTR2C | C0042656 | Neuralgia, Vidian | 1 | CTD_human |
| HTR2C | C0086189 | Drug Withdrawal Symptoms | 1 | CTD_human |
| HTR2C | C0087169 | Withdrawal Symptoms | 1 | CTD_human |
| HTR2C | C0234247 | Neuralgia, Atypical | 1 | CTD_human |
| HTR2C | C0234249 | Neuralgia, Stump | 1 | CTD_human |
| HTR2C | C0423711 | Neuralgia, Perineal | 1 | CTD_human |
| HTR2C | C0423712 | Neuralgia, Iliohypogastric Nerve | 1 | CTD_human |
| HTR2C | C0424295 | Hyperactive behavior | 1 | CTD_human |
| HTR2C | C0751217 | Hyperkinesia, Generalized | 1 | CTD_human |
| HTR2C | C0751371 | Neuralgia, Ilioinguinal | 1 | CTD_human |
| HTR2C | C0751372 | Nerve Pain | 1 | CTD_human |
| HTR2C | C0751373 | Paroxysmal Nerve Pain | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|